Conference Coverage
Trending on Targeted Onc
FDA Approves Giredestrant Plus Everolimus in ESR1-Mutated Breast Cancer
FDA Approves Pertuzumab Biosimilar in HER2-Positive Breast Cancer
FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC
Cretostimogene Cuts Recurrence Risk by 68% in Intermediate-Risk NMIBC
Tumor Treating Fields Improve Pain and Quality of Life in Pancreatic Cancer
Latest Content
Shorts










Podcasts

Dr Ligibel on Quality-of-Life Gains From the BWEL Weight Loss Program in Breast Cancer
Dr Jennifer Ligibel discusses BWEL quality-of-life results, why weight loss differed across groups, insurance barriers, and GLP-1 counseling.

The Patients Missing From Breast Cancer Data
Two researchers explain why Asian American and Hispanic patients with breast cancer are hard to see in the data, and what better data could change.

Beyond the Scan: Predicting Immunotherapy Response With ctDNA in NSCLC
Hear how a single ctDNA blood draw 3 to 9 weeks into immunotherapy may reveal response earlier than imaging in NSCLC, with Valsamo Anagnostou, MD, PhD.

Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.

Lung Cancer in Hispanic and Latinx Patients: Risk Factors, Biomarkers, and Clinical Trial Access
For Hispanic Heritage Month, Narjust Florez, MD, discusses lung cancer risk, biomarker testing, and trial access in Hispanic and Latinx patients.

Dr Jhaveri on the FDA Approval of Imlunestrant Plus Abemaciclib for ESR1-Mutated Breast Cancer
Komal Jhaveri, MD, discusses the FDA approval of imlunestrant plus abemaciclib for ESR1-mutated breast cancer, EMBER-3 data, and what's next.

Dr Herzberg on the Expanding Toolkit in KRAS-Mutant Non–Small Cell Lung Cancer
Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.

ASTRO 2026 Preview: Dr Raj Singh on De-Escalation, Brain Metastases, and What's Next in Radiation Oncology
Dr Raj Singh previews key ASTRO 2026 data, from FMISO PET-guided de-escalation in HPV-positive head and neck cancer to SRS vs whole brain radiotherapy trials in brain metastases.

Bringing CAR T and Bispecifics to the Community
How a community center launches CAR T and bispecific care: managing CRS/ICANS outpatient, closing access gaps, adapting to REMS.

Rethinking HER2: A Pan-Cancer Look at IHC, ERBB2, and Tumor-Agnostic Testing
Drs Aditya Shreenivas and Razelle Kurzrock break down a 200,000-tumor real-world study on HER2 IHC, ERBB2 alterations, and pan-cancer testing implications.
Videos
All News

FDA Approves Pertuzumab Biosimilar in HER2-Positive Breast Cancer
The approval of pertuzumab-qcay (Pebrilzo) covers metastatic and early-stage HER2-positive breast cancer, but a patent settlement with Genentech delays its earliest US launch until the third quarter of 2028.

Findings from the phase 3 PANOVA-3 trial showed that adding tumor treating fields to gemcitabine and nab-paclitaxel prolonged time to quality-of-life deterioration and improved pain outcomes in unresectable, locally advanced pancreatic cancer.

Adjuvant cretostimogene reduced recurrence risk vs surveillance after resection in the phase 3 PIVOT-006 trial in intermediate-risk and high-grade Ta NMIBC (HR, 0.32).

Mark A. Lewis, MD, explains when unexpected disease behavior in neuroendocrine tumors should prompt a specialist referral and how patients can still be treated close to home.

Updated LEGEND trial data show durable responses with detalimogene in BCG-unresponsive NMIBC, supporting a planned BLA submission by year-end 2026.

The FDA issued a complete response letter to the biologics license application for ivonescimab for use in combination with chemotherapy in EGFR-mutated NSCLC.

Crossover to bezuclastinib plus sunitinib after progression on sunitinib improved PFS and responses in GIST in phase 3 PEAK, with no new safety signals.

Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.

A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.

FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.

Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.

Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.

The NDA was completed for first-line zipalertinib plus platinum chemotherapy in EGFR exon 20 insertion NSCLC, based on phase 3 REZILIENT3 data showing improved PFS.

Telisotuzumab adizutecan showed promising survival in pretreated nonsquamous NSCLC, with the most benefit in EGFR wild-type tumors with high c-Met levels.

During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.

The FDA granted RMAT and fast track designations to prizloncabtagene autoleucel , a CD20/CD19 bispecific CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.

Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.

Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.

NCCN prostate cancer guidelines now list the ArteraAI Prostate Test (Post-RP), an AI tool that stratifies metastasis risk in biochemical recurrence after prostatectomy.

Eftilagimod alfa plus pembrolizumab and radiotherapy yielded 81.1% disease-free survival at 12 months in patients with resectable soft tissue sarcoma.

DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.

During a live event, Theresa Medina, MD, and participants discussed how disease site, BRAF status, and prior therapy guide treatment selection in metastatic melanoma.

The FDA has approved the PCR-based OncoMate MSI Dx Analysis System as a companion diagnostic to identify MSI-H solid tumors for treatment with pembrolizumab.

Anbal-cel demonstrated a 67.1% complete response rate in relapsed or refractory LBCL in the phase 1/2 CRC01-01 trial, evaluating dual PD-1 and TIGIT knockdown CAR T-cell therapy.

FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.

The phase 3 GIMEMA ALL2820 trial found improved event-free survival and molecular responses with frontline ponatinib plus blinatumomab vs imatinib and chemotherapy.

A study of more than 205,000 patients with advanced cancer found that physician and practice factors influence clinical trial enrollment, highlighting opportunities to improve access and address participation disparities.

Oncologists discuss long-term ibrutinib use, cardiovascular risks with BTK inhibitors, and emerging fixed-duration acalabrutinib-venetoclax therapy in CLL.

The FDA has approved pimicotinib (Pimjetmi) at 50 mg once daily for adults with symptomatic tenosynovial giant cell tumor, based on the phase 3 MANEUVER study.

Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.

Patients with relapsed or refractory CTCL who responded to denileukin diftitox-cxdl experienced improvements in skin-related quality of life and overall well-being in Study 302.

Among patients surveyed, 92% preferred home-based treatment, while nationwide modeling projected substantial savings in oncology resources.

During a live event, Pedro Barata, MD, MSc, and participating oncologists discussed how efficacy, tolerability, and clinical evidence inform subsequent-line treatment selection for metastatic clear cell renal cell carcinoma.



























































